Kura Oncology Inc reports results for the quarter ended June 30 - Earnings Summary

• Kura Oncology Inc KURA.OQ reported a quarterly adjusted loss of 75 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -59 cents. The mean expectation of thirteen analysts for the quarter was for a loss of 46 cents per share. Wall Street expected results to range from -86 cents to 3 cents per share.

• Revenue was $15.29 million​; analysts expected $36.66 million.

• Kura Oncology Inc's reported EPS for the quarter was a loss of 75 cents​.

• Kura Oncology Inc shares had risen by 4.5% this quarter and lost 30.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 1.9% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Kura Oncology Inc is $28.00, about 78.7% above its last closing price of $5.96

This summary was machine generated from LSEG data August 8 at 03:13 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)